文献速递认知障碍与痴呆

胆碱酯酶抑制剂对认知下降与死亡率的长期影响

Long-term Effects of Cholinesterase Inhibitors on Cognitive Decline and Mortality.
PubMed 文献 · Neurology · 2021-03-19

本研究基于瑞典痴呆登记处,纳入诊断后3个月内启用胆碱酯酶抑制剂(ChEI)的阿尔茨海默痴呆患者,并与未治疗患者进行倾向评分匹配。匹配队列含11,652例ChEI使用者与5,826例非使用者,平均随访5年。结果显示ChEI使用与每次访视MMSE评分较高相关(每年0.13分,95%CI 0.06-0.20),死亡风险降低27%(HR 0.73,95%CI 0.69-0.77);加兰他敏与死亡风险降低(0.71,95%CI 0.65-0.76)及重度痴呆风险降低(0.69,95%CI 0.47-1.00)相关,且对认知下降效果最强(每年0.18分,95%CI 0.07-0.28)。

要点

  • ChEI使用与阿尔茨海默痴呆患者每年MMSE评分较高0.13分相关,认知获益 modest 但持续。
  • ChEI使用者死亡风险较非使用者降低27%(HR 0.73,95%CI 0.69-0.77)。
  • 加兰他敏是唯一显著降低重度痴呆风险的ChEI(HR 0.69,95%CI 0.47-1.00)。

核心结论

  • ChEI与阿尔茨海默痴呆患者认知获益 modest 但持续相关,并与死亡风险降低相关。
  • 加兰他敏是唯一显示显著降低重度痴呆风险的ChEI。

研究设计与样本

  • 基于瑞典痴呆登记处的倾向评分匹配队列研究,纳入诊断后3个月内启用ChEI的阿尔茨海默痴呆患者,与非使用者比较。
  • 匹配队列含11,652例ChEI使用者与5,826例非使用者,平均随访5年。

主要发现

  • 随访期间255例发展为重度痴呆,6,055例(35%)死亡。
  • ChEI使用与每次访视MMSE评分较高相关(每年0.13分,95%CI 0.06-0.20)。
  • ChEI使用者死亡风险降低27%(HR 0.73,95%CI 0.69-0.77)。
  • 加兰他敏与死亡风险降低(HR 0.71,95%CI 0.65-0.76)及重度痴呆风险降低(HR 0.69,95%CI 0.47-1.00)相关。
  • 加兰他敏对认知下降效果最强(每年0.18 MMSE分,95%CI 0.07-0.28)。

关键数值与推荐

  • ChEI使用与每年MMSE评分较高0.13分相关(95%CI 0.06-0.20)。
  • ChEI使用者死亡风险HR 0.73(95%CI 0.69-0.77)。
  • 加兰他敏死亡风险HR 0.71(95%CI 0.65-0.76),重度痴呆风险HR 0.69(95%CI 0.47-1.00)。

临床怎么用

  • 对阿尔茨海默痴呆患者,ChEI治疗可能与长期认知下降减缓及死亡风险降低相关。
  • 加兰他敏可能对降低重度痴呆风险有额外益处,选择ChEI时可考虑。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate whether cholinesterase inhibitors (ChEIs) are associated with slower cognitive decline in Alzheimer dementia and decreased risk of severe dementia or death. METHODS: Patients with Alzheimer dementia from the Swedish Dementia Registry starting on ChEIs within 3 months of the dementia diagnosis were included and compared to nontreated patients with Alzheimer dementia. In a propensity score-matched cohort, the association between ChEI use and cognitive trajectories assessed by Mini-Mental State Examination (MMSE) scores was examined with a mixed model, and severe dementia (MMSE score <10) or death as an outcome was assessed with Cox proportional hazards models. RESULTS: The matched cohort included 11,652 ChEI users and 5,826 nonusers. During an average of 5 years of follow-up, 255 cases developed severe dementia, and 6,055 (35%) died. ChEI use was associated with higher MMSE score at each visit (0.13 MMSE points per year; 95% confidence interval [CI] 0.06-0.20). ChEI users had a 27% lower risk of death (0.73, 95% CI 0.69-0.77) compared with nonusers. Galantamine was associated with lower risk of death (0.71, 95% CI 0.65-0.76) and lower risk of severe dementia (0.69, 95% CI 0.47-1.00) and had the strongest effect on cognitive decline of all the ChEIs (0.18 MMSE points per year, 95% CI 0.07-0.28). CONCLUSIONS: ChEIs are associated with cognitive benefits that are modest but persist over time and with reduced mortality risk, which could be explained partly by their cognitive effects. Galantamine was the only ChEI demonstrating a significant reduction in the risk of developing severe dementia. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that for patients with Alzheimer dementia ChEIs decrease long-term cognitive decline and risk of death and that galantamine decreases the risk of severe dementia.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Xu H, Garcia-Ptacek S, Jönsson L, et al. Long-term Effects of Cholinesterase Inhibitors on Cognitive Decline and Mortality. Neurology. 2021. PMID: 33741639. doi:10.1212/WNL.0000000000011832

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。